GlassScriptPhysician profile
Ralph F Heaven
NPI 1023056280
$4,646.06
in general payments reported to CMS, 2019-2025
42 companies · $2,012 in 2025
The $2,012 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $162 · 2022: $97.43 · 2023: $733 · 2024: $986 · 2025: $2,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,464 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,463.55 |
| Education | $266.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $386.31 | 2019-2025 | Opdivo, Reblozyl, Augtyro |
| Abbvie INC. | $318.34 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $245.68 | 2024-2025 | Keytruda |
| Lilly USA, LLC | $224.05 | 2023-2024 | Jaypirca |
| Gilead Sciences, INC. | $218.76 | 2024-2025 | Trodelvy |
| Astellas Pharma US INC | $205.02 | 2019-2025 | Padcev, Xtandi |
| Glaxosmithkline, LLC. | $204.80 | 2023-2024 | Jemperli |
| Eisai INC. | $200.73 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $183.70 | 2019-2025 | Imfinzi, Enhertu |
| Pfizer INC. | $177.52 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.01 | 2025 | |
| Novartis Pharmaceuticals Corporation | $135.99 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.11 | 2025 | Fruzaqla, Ninlaro, Iclusig |
| Geron Corporation | $125.46 | 2025 | Rytelo |
| Kite Pharma, INC. | $117.06 | 2020 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $116.50 | 2024-2025 | |
| Verastem, INC. | $112.90 | 2019 | |
| Genzyme Corporation | $112.20 | 2024 | |
| Mirati Therapeutics, INC. | $111.12 | 2023 | Krazati |
| Regeneron Healthcare Solutions, INC. | $109.73 | 2025 | Libtayo, Lynozyfic |
| Pharmaessentia USA Corporation | $97.43 | 2022 | |
| Tempus Ai, INC | $97.30 | 2024 | |
| Exelixis INC. | $96.50 | 2019-2025 | Cabometyx |
| Daiichi Sankyo INC. | $93.30 | 2025 | Enhertu |
| Seagen INC. | $90.28 | 2023 | Adcetris |
| Dendreon Pharmaceuticals LLC | $78.55 | 2024 | Provenge |
| Genentech USA, INC. | $69.97 | 2025 | Tecentriq |
| Incyte Corporation | $69.73 | 2025 | Jakafi, Monjuvi |
| Pharmacosmos Therapeutics INC. | $56.10 | 2025 | Monoferric |
| Intuitive Surgical, INC. | $50.71 | 2023 | |
| Karyopharm Therapeutics INC. | $50.20 | 2025 | Xpovio |
| Immunocore Limited | $36.93 | 2025 | Kimmtrak |
| Stemline Therapeutics INC. | $33.25 | 2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $25.69 | 2025 | |
| Array Biopharma INC | $23.07 | 2025 | Tukysa, Mektovi, Braftovi |
| Taiho Oncology, INC. | $19.27 | 2025 | |
| Amgen INC. | $18.79 | 2025 | Imdelltra (Amg757) |
| Beigene USA, INC. | $14.61 | 2024 | Tevimbra |
| Shield Therapeutics INC | $13.97 | 2025 | |
| Clovis Oncology, INC. | $8.64 | 2019 | |
| Sirtex Medical INC | $8.51 | 2025 | Sir-Spheres Microspheres |
| Pharmaand Gmbh | $8.27 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Heaven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.